Search Results

Nicox SA, an international ophthalmology company, announced that the Ordinary and Extraordinary General Meetings were held today, on second convening.

Nicox SA, an international ophthalmology company, provided the revenue and cash position for Nicox SA and its subsidiaries for the first quarter of 2024 and financial results for Nicox SA for the full year of 2023, as approved by the Board of Directors on April 19, 2024, and provided an update on key future milestones.

Nicox SA, an international ophthalmology company, convenes an ordinary shareholder meeting on Friday June 28th, 2024 at 2:30 pm CEST in the offices of BuroClub – Drakkar 2 – Bâtiment D – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis – France.

Nicox SA provided financial and business highlights for the fourth quarter of 2023 for Nicox SA and its subsidiaries.

Nicox SA announced that the results from the Mont Blanc pivotal Phase 3 trial comparing NCX 470 to latanoprost in the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension have been published in the peer-reviewed journal American Journal of Ophthalmology.

Nicox SA, an international ophthalmology company, announced its Board of Directors has appointed the highly experienced biotech executive Gavin Spencer as Chief Executive Officer.

Nicox SA announced the signature of an agreement granting Kowa Company, Ltd., a Japanese company with a global pharmaceutical business engaged in ground-breaking research, development and marketing, exclusive Japanese rights to develop and commercialize NCX 470, Nicox’s nitric oxide (NO)-donating bimatoprost eye drop, for the lowering of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.